The FDA approves a new glioma therapy for the first time in decades, offering renewed hope for patients with this challenging brain cancer.

The U.S. Food and Drug Administration (FDA) has approved Vorasidenib for patients with Grade 2 gliomas harboring Isocitrate dehydrogenase 1 (IDH1)...

GSK plc, a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together, announced that the US...

A new study from the University of Michigan Health Rogel Cancer Center, USA, finds that giving a fatty acid inhibitor alongside chemotherapy could...

The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory...

Nova festival massacre survivors and soldiers will be part of a study combining individual and group therapy; 'I've seen MDMA-treated patients make...

FRIDAY, Aug. 16, 2024 -- For patients with hepatocellular carcinoma (HCC), immune checkpoint inhibitor (ICI) use prior to liver transplant (LT) does...

The 3D Urology and Prostate Clinics present their advanced 3D Targeted Therapy, offering effective and personalized prostate care solutions for...

Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets...

For decades, researchers have worked to develop therapies that can prime the immune system to recognize and attack proteins on the surface of tumor...